Introduction Mycoplasma genitalium (MG) is a sexually transmitted infection (STI) associated with urethritis in men and cervicitis and pelvic inflammatory disease (PID) in women. Azithromycin (AZ) resistance in MG, resulting in treatment failure is an issue. We compared molecular assays for detection of MG in females; a prospective cohort of adolescents with PID and a retrospective group of women at a STD clinic. We tested vaginal samples for AZ resistance with the SpeeDX assay, a real-time PCR, which detects MG and 23S rRNA AZ resistance mutations. Methods For the prospective study, SpeeDX results were compared to 16S rRNA and pdhD real-time PCR assays, and the Aptima MG ASR assay. Samples consisted of dry transported vaginal swab samples (n=116); expressed in water. For the retrospective study we evaluated vaginal samples (n=289) stored in liquid Amies media. Nucleic acid extraction was performed utilising the Roche MagNA Pure LC robot according to manufacturer instructions. The SpeeDX assay was performed according to manufacturer instructions. For the retrospective study, results were compared to the 2 real-time PCR assays for the 16S rRNA gene and pdhD gene. Results For the prospective study, a gold standard of 3 of 4 positive tests defined a true positive. The 16S PCR had 100% sensitivity (10/10) and 100% specificity (106/106) Kappa=1 [95% CI: 1-1], while SpeeDX PCR displayed 90% sensitivity (9/10) and 99% specificity (105/106) Kappa=0.89 [95% CI: 0.74-1]. The pdhD PCR had 100% sensitivity (10/10) and 100% specificity (106/106) Kappa=1. The Aptima MG assay had 90% sensitivity (9/10) and 94% specificity (100/106) . The SpeeDX 23S rRNA mutation rate was 50% (5/10). For the retrospective group, no Aptima MG was done because of transport media. A gold standard of 2 of 3 positive tests defined a true positive. The 16S PCR was 84% sensitive (21/25) and 100% specific (264/264) 
Introduction Mycoplasma genitalium (MG) is a sexually transmitted infection (STI) associated with urethritis in men and cervicitis and pelvic inflammatory disease (PID) in women. Azithromycin (AZ) resistance in MG, resulting in treatment failure is an issue. We compared molecular assays for detection of MG in females; a prospective cohort of adolescents with PID and a retrospective group of women at a STD clinic. We tested vaginal samples for AZ resistance with the SpeeDX assay, a real-time PCR, which detects MG and 23S rRNA AZ resistance mutations. Methods For the prospective study, SpeeDX results were compared to 16S rRNA and pdhD real-time PCR assays, and the Aptima MG ASR assay. Samples consisted of dry transported vaginal swab samples (n=116); expressed in water. For the retrospective study we evaluated vaginal samples (n=289) stored in liquid Amies media. Nucleic acid extraction was performed utilising the Roche MagNA Pure LC robot according to manufacturer instructions. The SpeeDX assay was performed according to manufacturer instructions. For the retrospective study, results were compared to the 2 real-time PCR assays for the 16S rRNA gene and pdhD gene. Results For the prospective study, a gold standard of 3 of 4 positive tests defined a true positive. The 16S PCR had 100% sensitivity (10/10) and 100% specificity (106/106) Kappa=1 [95% CI: 1-1], while SpeeDX PCR displayed 90% sensitivity (9/10) and 99% specificity (105/106) Kappa=0.89 [95% CI: 0.74-1]. The pdhD PCR had 100% sensitivity (10/10) and 100% specificity (106/106) Kappa=1. The Aptima MG assay had 90% sensitivity (9/10) and 94% specificity (100/106) . The SpeeDX 23S rRNA mutation rate was 50% (5/10). For the retrospective group, no Aptima MG was done because of transport media. A gold standard of 2 of 3 positive tests defined a true positive. The 16S PCR was 84% sensitive (21/25) and 100% specific (264/ Introduction Point-of-care syphilis testing currently uses fingerstick blood to identify Treponema pallidum (TP) antibodies by qualitative immunoassay. However, oral fluid testing is highly preferred by patients. We aimed to determine if rapid tests intended for whole blood could be used to detect treponemal antibody in oral fluid. Methods Oral fluid was collected at the UCLA Care Clinic from 49 participants using Oasis SuperSAL (Vancouver, WA). The device uses an absorbent cylindrical pad to collect and filter~1 mL of oral fluid. Oral fluid filtrate was evaluated with 3 rapid syphilis tests: SD Bioline Syphilis 3.0 (SD), MedMira Reveal TP (MM), and First Response Anti-TP (FR) following manufacturer directions for whole blood. Reference test results, TP particle agglutination (TPPA) and rapid plasma reagin (RPR), were extracted from participants' medical records. We used 3 different definitions as a reference standard. Definition 1: TPPA reactive. Definition 2: TPPA and RPR reactive. Definition 3: TPPA reactive and RPR titer >1:4. Specimens nonreactive on both the TPPA and RPR were considered negative. We calculated specificity and sensitivity for each definition, and used the exact binomial method to determine 95% confidence intervals (CI). Results With definitions 1, 2 and 3 respectively, SD sensitivity was 86.4% (CI: 65.1, 97.1), 93% (CI: 66.1,99.8), 100% (CI: 59.0,100); MM sensitivity was 6.3% (CI: 0.2,30.2), 9.1% (CI: 0.2,41.2), 16.7% (CI: 0.4,64.1); and FR sensitivity was 25% (CI: 8.7,49.1), 25% (CI: 5.5,57.2), 14.3% (CI: 0.4,57.9). SD specificity was 56% (CI: 36.5,75.5), MM specificity was 100% (CI: 35.9,99.6) and FR specificity was 100% (CI: 83.9,100). Conclusion The high sensitivity of the SD test suggests a strong potential for oral fluid-based rapid syphilis testing. SD sensitivity increased with RPR titer. False positive results may be associated with the presence of non-venereal treponemal antibodies in oral fluid. The MM and FR tests had low sensitivity, perhaps due to differences in treponemal targets. Further research and development are needed.
